Advancing Antibody-Based Therapies

We are Patient Centric

We are Science-Based

We are Performance Driven

Immunomedics Company Update

The Company will host a conference call and live audio webcast on January 18, 2019 at 8:00 am Eastern Time. To access the conference call, click here.

37th Annual J.P. Morgan Healthcare Conference

On Thursday, January 10, 2019 at 7:30am Pacific Time, Michael Pehl, President and Chief Executive Officer, will present an overview of the Company and its strategic priorities at the 37th Annual J.P. Morgan Healthcare Conference.

More Information

Our Drive to Improve Targeted Therapies of Diseases

We have assembled significant expertise in antibody engineering, particularly proprietary CDR-grafting methods, antibody production and formulation, immunochemistry, molecular biology, antibody conjugation, peptide chemistry, synthetic organic chemistry, and protein engineering.

Our Science


We believe that each of our antibodies has therapeutic potential either when administered as a naked antibody or when conjugated with therapeutic radioisotopes (radiolabeled), chemotherapeutics, cytokines or other toxins to create unique and potentially more effective treatment options.

Learn More

Explore how we turn our research into reality.

Immunomedics is sponsoring an international Phase 3 clinical trial in patients with relapsed triple-negative breast cancer who have previously received two or more therapies for their metastatic disease.

Clinical Trials